X4 Pharmaceuticals (XFOR) Receivables - Other (2017 - 2025)
X4 Pharmaceuticals (XFOR) posted Receivables - Other of $715000.0 for Q3 2025, down 0.69% on a QoQ basis from $720000.0 in Q2 2025, and down 33.36% year-over-year from $1.1 million in Q3 2024.
X4 Pharmaceuticals (XFOR) Receivables - Other (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals' Receivables - Other history runs 9 years deep, the most recent figure standing at $715000.0 for Q3 2025.
- Quarterly Receivables - Other fell 33.36% year-over-year to $715000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $715000.0 (down 33.36% YoY) and the FY2024 annual result came in at $640000.0, up 13.88% from the prior year.
- Receivables - Other was $715000.0 for Q3 2025 at X4 Pharmaceuticals, down from $720000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $1.2 million in Q4 2022 and bottomed at $393000.0 in Q3 2023.
- A 5-year average of $778315.8 and a median of $747000.0 in 2021 frame the typical range for Receivables - Other.
- Annual changes were most pronounced in 2023 — Receivables - Other tumbled 56.77% — and 2024, when it surged 173.03%.
- X4 Pharmaceuticals' Receivables - Other stood at $747000.0 in 2021, then jumped by 54.22% to $1.2 million in 2022, then slumped by 51.22% to $562000.0 in 2023, then increased by 13.88% to $640000.0 in 2024, then advanced by 11.72% to $715000.0 in 2025.
- Business Quant data shows XFOR's Receivables - Other at $715000.0 in Q3 2025, $720000.0 in Q2 2025, and $665000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | X4 Pharmaceuticals | 167.90 Mn | -49.15 Mn | 2.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 715,000.00 |
| Sep 30, 2025 | 715,000.00 |
| Jun 30, 2025 | 720,000.00 |
| Jun 30, 2025 | 720,000.00 |
| Mar 31, 2025 | 665,000.00 |
| Mar 31, 2025 | 665,000.00 |
| Dec 31, 2024 | 640,000.00 |
| Dec 31, 2024 | 640,000.00 |
| Sep 30, 2024 | 1.07 Mn |
| Sep 30, 2024 | 1.07 Mn |
| Jun 30, 2024 | 854,000.00 |
| Jun 30, 2024 | 854,000.00 |
| Mar 31, 2024 | 702,000.00 |
| Mar 31, 2024 | 702,000.00 |
| Dec 31, 2023 | 562,000.00 |
| Dec 31, 2023 | 562,000.00 |
| Sep 30, 2023 | 393,000.00 |
| Sep 30, 2023 | 393,000.00 |
| Jun 30, 2023 | 820,000.00 |
| Jun 30, 2023 | 820,000.00 |